ATYR — aTyr Pharma Income Statement
0.000.00%
Last trade - 00:00- $319.89m
- $249.01m
- $0.24m
- 15
- 4
- 100
- 33
Annual income statement for aTyr Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 10.5 | 0 | 10.4 | 0.353 | 0.235 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 26.4 | 34 | 56.8 | 55.3 | 68.1 |
| Operating Profit | -15.9 | -34 | -46.4 | -54.9 | -67.9 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -16.2 | -33.8 | -45.3 | -50.4 | -64 |
| Net Income After Taxes | -16.2 | -33.8 | -45.3 | -50.4 | -64 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -16.2 | -33.8 | -45.3 | -50.4 | -64 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -16.2 | -33.8 | -45.3 | -50.4 | -64 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.77 | -1.77 | -1.6 | -0.94 | -0.862 |